98%
921
2 minutes
20
Opioid analgesics are commonly prescribed after total knee and hip arthroplasty to manage pain. Rates of opioid prescribing after arthroplasty differ by country, suggesting differences in policies or surgeons' practices. We adopted a qualitative description design to explore and compare Canadian, Dutch, and Japanese orthopaedic surgeons' perceptions of facilitators and barriers to opioid reduction after total joint arthroplasty. We used a combination of convenience and purposive sampling, and snowball recruitment to facilitate 27 semi-structured interviews online or via a phone call. We concurrently collected and analyzed data using conventional (inductive) content analysis. In our sample, all Canadian surgeons and almost all Dutch surgeons prescribed opioids to all arthroplasty patients post-discharge. Surgeons in Japan showed much greater variability, with half of those interviewed prescribing opioids to only a minority or no patients post-discharge. Japanese surgeons indicated that a 10-30-day hospital stay was typical after surgery and believed that opioids were often unnecessary for managing postoperative pain. Dutch surgeons described using an institutional standard pain management protocol, while Canadian and Japanese surgeons noted high variability in the type and dose of opioids prescribed, even within the same institution. Orthopaedic surgeons in each country identified challenges and facilitators to reduced postoperative opioid use in six key areas: (1) opioid prescribing practices, (2) patient factors, (3) collaborative care, (4) opioid prescribing policies/guidelines, (5) surgeon education, and (6) personal perceptions/beliefs. Canadian, Dutch, and Japanese orthopedic surgeons in our study described a range of individual, patient, and system level contributors to variability in opioid prescribing after joint replacement surgery. These findings suggest that multifactorial and context-specific approaches may be required to address barriers and optimize postoperative use of opioids.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12396690 | PMC |
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0331335 | PLOS |
Perm J
September 2025
Department of Pharmacy, Kaiser Permanente Georgia, Atlanta, GA, USA.
Background: Opioids are highly effective for pain management but carry risks. Naloxone quickly reverses opioid overdoses by blocking opioid receptors in the brain. Despite its effectiveness, naloxone remains underutilized.
View Article and Find Full Text PDFArch Psychiatr Nurs
October 2025
University of Pittsburgh School of Nursing, Department of Health and Community Systems, 3500 Victoria St. Pittsburgh, PA 15213, United States of America. Electronic address:
Background: Women veterans are at risk for substance use and substance use disorders, although there remains limited data on substance use in women veterans.
Methods: A secondary analysis of data from the National Survey on Drug Use and Health from 2015 to 2019 and 2021 was conducted to compare women veterans with women non-veterans and men veterans on substance-related outcomes, including lifetime substance use, frequency of past 30-day substance use, and past-year substance use disorders for cannabis, opioids, and stimulants.
Results: From 2015 to 2019, women veterans were about 53 % and 24 % more likely to have used cannabis in their lifetime compared to women non-veterans and men veterans, respectively.
Cochrane Database Syst Rev
September 2025
Department of Family Medicine, University of Alberta, Edmonton, Alberta, Canada.
Background: Opioid use disorder (OUD) is commonly treated in specialized care settings with long-acting opioid agonists, also known as opioid agonist therapy, or OAT. Despite the rise in opioid use globally and evidence for a 50% reduction in mortality when OAT is employed, the proportion of people with OUD receiving OAT remains small. One initiative to improve the access and uptake of OAT could be to offer OAT in a primary care setting; primary care clinics are more numerous, might reduce the visibility and potential stigma of receiving treatment for OUD, and may facilitate the care of other medical conditions that are unrelated to OUD.
View Article and Find Full Text PDFJ Law Med Ethics
September 2025
Dalla Lana School of Public Health, https://ror.org/03dbr7087University of Toronto, Canada.
The opioid overdose crisis has become a global public health emergency, claiming more than 100,000 lives each year. In North America, shifting opioid prescribing practices in response to the crisis have profoundly affected people living with chronic pain, who now face reduced access to prescription opioids. Against this backdrop, pain stakeholders have become increasingly active in policymaking arenas to shape how opioids and pain are understood.
View Article and Find Full Text PDFCancer
September 2025
Department of Biostatistics, Brown University School of Public Health, Providence, Rhode Island, USA.
Background: Opioid exposure during cancer therapy may increase long-term unsafe opioid prescribing. This study sought to determine the rates of coprescription of benzodiazepine and opioid medications and new persistent opioid use after surgical treatment of early-stage cancer.
Methods: A retrospective cohort study was conducted among a US veteran population via the Veterans Affairs Corporate Data Warehouse database.